Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease

[1]  F. Cicchetti,et al.  The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration , 2011, Journal of Neuroinflammation.

[2]  F. Cicchetti,et al.  The critical role of the MyD88-dependent pathway in non-CNS MPTP-mediated toxicity , 2011, Brain, Behavior, and Immunity.

[3]  W. Poewe,et al.  Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. , 2011, The American journal of pathology.

[4]  W. Oertel,et al.  Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease , 2011, Journal of Neuroimmunology.

[5]  S. Chasovskikh,et al.  α-Synuclein Alters Toll-Like Receptor Expression , 2011, Front. Neurosci..

[6]  E. Hirsch,et al.  Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism , 2011, Proceedings of the National Academy of Sciences.

[7]  Andrew E. Parker,et al.  Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.

[8]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[9]  C. Kendziorski,et al.  Quantitative trait loci associated with susceptibility to bladder and kidney infections induced by Escherichia coli in female C3H/HeJ mice. , 2009, The Journal of infectious diseases.

[10]  E. Hirsch,et al.  Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. , 2008, The Journal of clinical investigation.

[11]  E. Hirsch,et al.  Modelling Parkinson‐like neurodegeneration via osmotic minipump delivery of MPTP and probenecid , 2008, Journal of neurochemistry.

[12]  W. Rostène,et al.  The chemokine stromal cell‐derived factor‐1/CXCL12 activates the nigrostriatal dopamine system , 2007, Journal of neurochemistry.

[13]  R. Coffman,et al.  Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists , 2007, Nature Medicine.

[14]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[15]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[16]  S. Rivest,et al.  Toll‐like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram‐negative bacterial cell wall components , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Richard J Smeyne,et al.  Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus , 1999, Brain Research.

[18]  P. Ricciardi-Castagnoli,et al.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.

[19]  Acknowledgements , 1992, Experimental Gerontology.

[20]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[21]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[22]  K. Maguire-Zeiss,et al.  Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. , 2012, Parkinsonism & related disorders.

[23]  G. Nicolardi,et al.  Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. , 2008, Immunopharmacology and immunotoxicology.

[24]  K. Yueh,et al.  A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females. , 2006, Parkinsonism & related disorders.